DHFB
SUPN icon

Dixon Hubard Feinour & Brown’s Supernus Pharmaceuticals SUPN Stock Holding History

Dixon Hubard Feinour & Brown’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-62,680
Closed -$2.08M – 177
2018
Q4 		$2.08M Sell
62,680
-25,835
-29% -$1.11M 0.77% 38
2018
Q3 		$4.46M Buy
88,515
+685
+0.8% +$33.8K 1.23% 29
2018
Q2 		$5.26M Buy
+87,830
New +$4.55M 1.53% 23

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
NPIC
Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dixon Hubard Feinour & Brown's SUPN Position: Q1 2019 in Review

Dixon Hubard Feinour & Brown sold out of Supernus Pharmaceuticals (SUPN) in Q1 2019, closing a stake of 62,680 shares — an estimated $2.08M sold.

Dixon Hubard Feinour & Brown first reported a position in SUPN in Q2 2018 and held it in 3 quarters. The position peaked at $5.26M in Q2 2018. 289 funds tracked by Wall St. Rank hold SUPN as of Q1 2019.

  • Dixon Hubard Feinour & Brown reported no remaining Supernus Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Dixon Hubard Feinour & Brown sold 62,680 Supernus Pharmaceuticals shares in Q1 2019, an estimated $2.08M.
  • Dixon Hubard Feinour & Brown first reported a position in Supernus Pharmaceuticals in Q2 2018 and held it in 3 quarters.
  • Dixon Hubard Feinour & Brown's Supernus Pharmaceuticals position peaked at $5.26M in Q2 2018.
  • 289 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2019.

Based on Dixon Hubard Feinour & Brown's 13F filing for Q1 2019, filed 17 May 2019.